沙库巴曲缬沙坦联合达格列净治疗射血分数保留的心力衰竭的临床效果分析  

Analysis of Clinical Effect of Sacubitril Valsartan Combined with Dapagliflozin in Treatment of Heart Failure with Preserved Ejection Fraction

作　　者：唐敏 Tang Min(Department of Cardiology,Tongshan District People's Hospital of Xuzhou City,Xuzhou 221006,Jiangsu Province,China)

机构地区：[1]徐州市铜山区人民医院心内科,江苏徐州221006

出　　处：《中国社区医师》2025年第8期18-20,共3页Chinese Community Doctors

摘　　要：目的:探究对于射血分数保留的心力衰竭(HFpEF)患者采用沙库巴曲缬沙坦联合达格列净治疗的临床效果。方法:选取120例HFpEF患者进行研究,均选自2022年12月—2024年6月徐州市铜山区人民医院心内科,采用随机数字表法分成2组,每组纳入60例。对照组采用沙库巴曲缬沙坦治疗,观察组在对照组基础上采用达格列净治疗。比较两组治疗效果。结果:治疗后,两组三尖瓣环收缩期位移增加,且观察组长于对照组(P<0.05);两组收缩期峰值运动速度、右心室面积变化率增大,且观察组大于对照组(P<0.05);两组肺动脉收缩压升高,且观察组高于对照组(P<0.05);两组可溶性生长刺激表达基因2蛋白、N端脑利钠肽前体、超敏C反应蛋白、白细胞介素-6水平均降低,且观察组低于对照组(P<0.05)。治疗3、6个月后,两组6 min步行距离延长,且观察组较对照组长(P<0.05)。结论:沙库巴曲缬沙坦联合达格列净治疗HFpEF的临床效果显著,可改善患者的右心室功能,降低炎性因子水平。Objective:To investigate the clinical effects of sacubitril-valsartan combined with dapagliflozin in patients with heart failure with preserved ejection fraction(HFpEF).Methods:A total of 120 patients with HFpEF were selected from the Department of Cardiology,Tongshan District People's Hospital of Xuzhou City from December 2022 to June 2024,and were divided into two groups by random number table method,and 60 cases were included in each group.The control group was treated with sacubitrilvalsartan,and the observation group was treated with dapagliflozin on the basis of the control group.Results:After treatment,the tricuspid annular plane systolic excursion in the two groups increased,and this parameter in the observation group was longer than that in the control group(P<0.05).The systolic peak movement velocity and right ventricular area change rate in the two groups increased,and these parameters in the observation group were larger than those in the control group(P<0.05).The pulmo⁃nary arterial systolic blood pressure in the two groups increased,and this parameter in the observation group was higher than that in the control group(P<0.05).The levels of soluble growth-stimulating expression gene 2 protein,N terminal brain natriuretic pep⁃tide precursor,hypersensitive C-reactive protein and interleukin-6 in the two groups decreased,and the levels in the observation group were lower than those in the control group(P<0.05).After 3 and 6 months of treatment,the 6-min walking distance in the two groups prolonged,and this parameter in the observation group was longer than that in the control group(P<0.05).Conclusion:Sacubitril valsartan combined with dapagliflozin has significant clinical effect in the treatment of HFpEF,and can improve the right ventricular function of patients and reduce the levels of inflammatory factors.

关 键 词：沙库巴曲缬沙坦 达格列净 射血分数保留的心力衰竭 右心室功能 炎性因子 

分 类 号：R541.6[医药卫生—心血管疾病]